Amiodarone pulmonary toxicity: Cytopathology, ultrastructure, and immunocytochemistry

Annals of Diagnostic Pathology

Volumn 1, Issue 1, 1997, Pages 47-56

  Bedrossian, Carlos W M ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Amiodarone; Drug toxicity; Phospholipidosis; Pulmonary toxicity

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BIOLOGICAL MARKER; PHOSPHOLIPID;

ADULT; AGED; ARTICLE; BIOPSY; CELL COUNT; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DRUG EFFECT; ENZYME IMMUNOASSAY; FEMALE; FOAM CELL; HUMAN; LIPIDOSIS; LUNG DISEASE; LUNG LAVAGE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; ULTRASTRUCTURE;

ADULT; AGED; AGED, 80 AND OVER; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; BIOLOGICAL MARKERS; BIOPSY; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; FEMALE; FOAM CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; LIPIDOSES; LUNG DISEASES; MALE; MIDDLE AGED; PHOSPHOLIPIDS; PROSPECTIVE STUDIES;

EID: 0031240575     PISSN: 10929134     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1092-9134(97)80008-1     Document Type: Article

References (2)

1. Colgan T, Simon GT, Kay JM, et al: Amiodarone pulmonary toxicity. Ultrastructural Pathol 1984:6:199-207
2. Heger JJ, Prystowsky EN, Zipes DP: Clinical efficacy of amiodarone in treatment of recurrent ventricular tachycardia and ventricular fibrillation. Am Heart J 1983;106:887-894